Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: August 3, 2020
Expires: August 3, 2021
30 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Review unmet needs in the care of multiple myeloma (MM) and the potential role of immunotherapies such as antibodies, antibody-drug conjugates, CAR T-cells, and others
  • Evaluate clinical trial data of current and emerging immunotherapies being examined in patients with MM
  • Assess unique adverse event profiles of immunotherapies that differ from traditional therapies used for the treatment of patients with MM
  • Develop strategies to integrate immunotherapies into the MM treatment paradigm as they become available

Activity Description

Expert Insights is a summary of a virtual satellite symposium from the 2020 Clinical Oncology Meeting and will discuss current data of current and emerging immunotherapeutic-based approaches for the treatment of patients with multiple myeloma.

Statement of Educational Need

Given the recent approval of immunotherapies for the treatment of patients with multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with MM.


  • Unmet needs
  • Monoclonal antibodies
  • BiTEs
  • Vaccines
  • ADCs
  • CAR T-cells


Saad Z. Usmani, MD, FACP
Chief, Plasma Cell Disorders Division
Director, Clinical Research in Hematologic Malignancies
Department of Hematologic Oncology & Blood Disorders
Levine Cancer Institute
Charlotte, North Carolina

Consulting Fees: Amgen Inc., Bristol Myers Squibb, Celgene Corporation, GlaxoSmithKline, Janssen Oncology, Merck & Co., Sanofi, SkylineDX, Takeda Pharmaceutical Company

Contracted Research & Publishing: Amgen Inc., Array BioPharma, Bristol Myers Squibb, Celgene Corporation, GlaxoSmithKline, Janssen Oncology, Merck & Co., Pharmacyclics LLC, Sanofi, Seattle Genetics, SkylineDX, Takeda Pharmaceutical Company

Speaker’s Bureau: Amgen Inc., Celgene Corporation, Janssen Oncology, Sanofi, Takeda Pharmaceutical Company

Krina Patel, MD, MSc
Assistant Professor
Department of Lymphoma and Myeloma
Assistant Professor
Department of Stem Cell Transplantation
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Consulting Fees: Bristol Myers Squibb, Celgene Corporation, Cellectis, Janssen Oncology, Nektar Therapeutics, Pfizer Inc., Poseida Therapeutics, Inc., Precision BioSciences

Contracted Research & Publishing: AbbVie Inc., Bristol Myers Squibb, Celgene Corporation, Cellectis, Janssen Oncology, Nektar Therapeutics, Poseida Therapeutics, Inc., Precision BioSciences

Conflict of Interest Policy/Disclosure Statement

Faculty and Planning Committee Disclosures

As a provider accredited by ACCME, the UNMC Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

Continuing Education

The University of Nebraska Medical Center (UNMC), Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

The UNMC Center for Continuing Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of the UNMC Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Materials will be available online through August 3, 2021.

Statement of Commercial Support

This activity is supported by independent educational grants from Legend Biotech and Sanofi Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.